The resistance of the lung cancer cells to irinotecan (CPT-11) and its active metabolite SN38 is associated with the elevated expression of PXR downstream genes UGT1A1 and UGT1A10 137. This evidence concerns the gene UGT1A10 and lung carcinoma.